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• Osteoarthritis (OA) is the most common form of arthritis and 
affects about 27 million Americans, more commonly women.1
• Many factors lead to OA such as natural age progression, joint 
integrity, genetics, inflammation, weight, and mechanical forces.1
• OA of the knee accounts for 1 of 5 leading causes of disability 
among institutionalized adults2
• 40% of adults with knee OA report their health as “fair” or poor.”2
• Evaluating all forms of arthritis begins with measuring the width 
of the affected joint space. This allows providers to track the 
progression of the cartilage degeneration through scoring and 
grading.3
• New therapies are interested in slowing the rate of joint space 
narrowing.
• Glucosamine and chondroitin sulfate are two dietary supplements 
available over the counter that were initially used for symptomatic 
relief of OA but have been targeted recently for their use in the 
treatment of joint space narrowing.3
Figure 1: PRISMA Flow Diagram 
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There is a potential protective effect of glucosamine and chondroitin 
sulfate, especially if used in combination, on joint space narrowing in 
patients with knee osteoarthritis with at least two years of daily use. 
Patients with a KL grade of one or two are more likely to benefit from 
these two supplements. However, more research over a longer 
duration of time, greater than two years, is needed to definitively 
conclude that glucosamine and chondroitin sulfate are effective in 
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Population Adults (>18 years old) with knee osteoarthritis 
Intervention Glucosamine, chondroitin sulfate, or glucosamine + 
chondroitin sulfate
Comparison Placebo 
Outcome Patient’s functional outcome as indicated by mean 







Objective Evaluate the effects of 
glucosamine and 
chondroitin sulfate, alone or 
in combination, as well as 
celecoxib and placebo on 
the progressive loss of joint 
space width in patients with 
knee osteoarthritis
Evaluate effects of 
glucosamine sulfate, 
chondroitin sulfate and their 
combination in reducing 
structural disease 
progression, pain relief, and 
improvement in functional 
status.  
Assess the structural 
efficacies of daily 
glucosamine sulfate and 
chondroitin sulfate in 
patients with knee 
osteoarthritis. 
Study Type Double-blind RCT Double-blind RCT Meta-Analysis
Sample Size 357 605 1,502
Study Treatments glucosamine 500 mg TID
chondroitin sulfate 400 mg 
TID
combination G + CS
Celecoxib 200 mg QD
glucosamine 753 mg QD
chondroitin sulfate 400 mg 
QD
Combination G + CS
glucosamine 1,500 mg QD
chondroitin sulfate 400 mg 
or 800 mg QD
Comparison Placebo Placebo Placebo
Follow Up Periods 2 years 1 year, 2 years G: 1 year, 3 years
CS: 2 years
Female (%) 63% 56% 67%
BMI, mean (kg/m2) or 
%
25-30 kg/m2= 34.7%
>30 kg/m2= 53.2% 
28.9 27.4
K/L Grade of >3 (%) 23% 47% n/a
Pain scale at baseline 
and at the end of 
follow up period (0-10, 
mean)
n/a G = 4.7, 3.86
C = 4.6, 3.76
G + C = 4.7, 3.58
Placebo = 4.8, 4.03
n/a
Mean joint space 
narrowing at end of 
follow up period in 
(mm or SMD with 
95% confidence 
interval)
G = 0.013 mm 
CS = 0.107 mm
G + CS = 0.194 mm
Celecoxib = 0.111 mm
Placebo = 0.166 mm
G = 0.24 mm
CS = 0.20 mm
G + CS = 0.12 mm
Placebo = 0.22 mm
G (SMD) = 0.432
(0.235 - 0.628)
CS (SMD) = 0.261 (0.131-
0.392) 
Conclusion No statistically significant 
effects on JSN in all 
treatment allocations
Statistically significant 
effect on JSN in 
combination G + CS at 2 
years of daily use
Statistically significant 
effect on JSN in chondroitin 
and glucosamine 
individually with long-term 
daily use of at least three 
and two years, respectively
Limitations - Small sample size
- Small group of 
qualifying follow up x-
ray films
- Intention to treat analysis
- Minimal number of 
participants with severe 
JSW or KL grade 3-4.
- Intention to treat analysis
- Small number of studies
- Varying formulations 
and dosage frequencies
- Intention to treat analysis
Table 2. Overview of studies included in the systematic review. RCT = randomized controlled trial; QD = four times a day; TID = three times 
a day; G = glucosamine; CS = chondroitin sulfate; BMI = body mass index; SMD = standard mean difference; K/L = Kellgren and Lawrence; 
JSN = joint space narrowing 
Table 1. Components (population, intervention, comparison and outcome) of the 
clinical question 
Figure 2. Radiographic measurement of joint space width of the medial tibio-femoral 
compartment with full extension (left) and 45 degree flexion (right) views.7
